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BACKGROUND AND PURPOSE 
White matter hyperintensities (WMHs) detected by magnetic resonance imaging (MRI) 
of the brain are associated with dementia and cognitive impairment in the general 
population and in Alzheimer's disease. Their effect in cognitive decline and dementia 
associated with Parkinson's disease (PD) is still unclear. 
 
METHODS 
We studied the relationship between WMHs and cognitive state in 111 patients with PD 
classified as cognitively normal (n = 39), with a mild cognitive impairment (MCI) (n = 
46) or dementia (n = 26), in a cross-sectional and follow-up study. Cognitive state was 
evaluated with a comprehensive neuropsychological battery, and WMHs were identified 
in FLAIR and T2-weighted MRI. The burden of WMHs was rated using the Scheltens 
scale. 
 
RESULTS 
No differences in WMHs were found between the three groups in the cross-sectional 
study. A negative correlation was observed between semantic fluency and the subscore 
for WMHs in the frontal lobe. Of the 36 non-demented patients re-evaluated after a 
mean follow-up of 30 months, three patients converted into MCI and 5 into dementia. 
Progression of periventricular WMHs was associated with an increased conversion to 
dementia. A marginal association between the increase in total WMHs burden and 
worsening in the Mini Mental State Examination was encountered. 
 
CONCLUSIONS 
White matter hyperintensities do not influence the cognitive status of patients with PD. 
Frontal WMHs have a negative impact on semantic fluency. Brain vascular burden may 
have an effect on cognitive impairment in patients with PD as WMHs increase overtime 
might increase the risk of conversion to dementia. This finding needs further 
confirmation in larger prospective studies. 
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INTRODUCTION 
 
Dementia occurs in nearly 80% of patients with Parkinson's disease (PD) [1,2]. It has 
been associated with cortical Lewy bodies (LB), amyloid plaques, neurofibrilary tangles 
[3], and cholinergic deficit [4]. Cerebrovascular (CV) lesions have been proposed to 
influence dementia in PD, although this remains to be clearly demonstrated [5–8]. Silent 
vascular lesions, identified as white matter hyperintensities (WMHs) [9], are associated 
with dementia in the general population [10–12], and they are thought to aggravate 
cognitive impairment in Alzheimer's disease (AD) [13] and LB disease [14]. Moreover, 
WMHs are linked to an in-creased risk of cognitive decline in the elderly and to mild 
cognitive impairment (MCI) in the general population [15]. The relationship between 
dementia [16–18] and MCI [16,17,19] in PD and WMHs is controversial. Therefore, we 
analyzed WMHs in cerebral magnetic resonance images (MRI) from a large cohort of 
patients with PD using a cross-sectional and longitudinal design, to assess the possible 
relationship between silent vascular lesions and dementia or MCI in this population. 
 
 
 
PATIENTS AND METHODS 
 
The Ethics Committee for Medical Research of the Clinic Universidad de Navarra 
approved the study, and all participants, or legal representatives, provided their written 
informed consent. 
 
Patients with PD [21] over 60 years of age and with disease duration of at least 10 years 
were recruited. Patients with other neurological or psychiatric disorders, severe systemic 
or vascular disease (stroke, ischaemic heart disease, atherosclerosis, arterial by-pass 
surgery), or previous cerebral surgery were excluded. Other vascular risk factors 
obtained by clinical history, interview, and blood tests were recorded but did not 
constitute exclusion criteria (Table 1). The Hoehn & Yahr scale and the Unified 
Parkinson's Disease Rating Scale – motor section (UPDRS-III) were used to evaluate 
disease severity. Patients were classified as showing normal cognition (PDCN), mild 
cognitive impairment (PD-MCI), or dementia (PDD). DSM-IV criteria were applied to 
diagnose dementia. MCI was diagnosed in non-demented patients when (i) cognitive 
decline was reported by either the patient or informant, or observed by the neurologist, 
but it did not interfere significantly with functional independence of the patient; (ii) the 
patient scored more than 1.5 standard deviations below the mean for age- and 
education-appropriate test norms in at least two tests in the neuropsychological battery, 
either within a single cognitive domain or across different cognitive domains [22]. 
 
Parkinson's disease patients without cognitive symptoms and with normal performance 
in the battery tests were considered as PDCN. For the follow-up study, PDCN and PD-
MCI patients were re-evaluated 12–48 months after initial assessment. 
 
The primary aim of this study was to determine the relationship between silent vascular 
lesions identified as WMHs and cognitive impairment in patients with PD using cross-
sectional and longitudinal approaches. A secondary objective was to evaluate how the 
distribution of WMHs might affect specific cognitive domains. 
 
 
 
Neuropsychological evaluations 
 
A trained neuropsychologist performed the following evaluations in patients under the 
effect of dopaminergic treatment as published elsewhere [23]. Global cognitive function 
was evaluated using the Mini Mental State Examination (MMSE) and the Blessed 
Dementia Scale. Daily activities were rated using the Interview for Deterioration in 
Daily Living in Dementia scale (IDDD). Depression was assessed by the Yesavage 
Geriatric Depression Rating Scale (GDS). Different cognitive domains were evaluated 
as follows: verbal episodic memory – Buschke Free and Cued Selective Reminding Test 
and CERAD word list; visual episodic memory – copy and delayed recall of two simple 
figures (Massachusetts General Hospital of Boston); language – Boston naming test; 
attention and executive functions – Raven progressive matrices, semantic “animals” and 
phonetic “words starting with p” verbal fluency, trail making test A and B and the 
Stroop test. The tests and the diagnostic criteria were used to determine the cognitive 
state of each subject. 
 
 
Magnetic resonance imaging 
 
A brain MRI study was carried out using a 1.5-T MRI scanner MagnetonSP (Siemens, 
Erlangen, Germany), including FLAIR (TR/TE/TI:8150/125/2500, flip angle 15% 
matrix size 256 x 179, yielding 10 coronal slices with a slice thickness of 5 mm and in-
plane resolution of 0.78 x 0.78 mm), T2- and T1-weighted MPRAGE sequences. Silent 
vascular brain burden was analyzed as the presence of WMHs, which were defined as 
hyperintense lesions in both FLAIR and T2-weighted axial MRI sequences. In each 
patient, the MRI, and the neuropsychological and physical evaluations were performed 
within the same week. Throughout the study, there was no change in the MRI scanner 
or in the methodology applied to obtain the images. 
 
 
White matter hyperintensities rating 
 
White matter hyperintensities were assessed by two trained neurologists blind to the 
cognitive diagnosis using the semiquantitative visual rating scale of Scheltens [24]. The 
scale is divided into four subscales rating different brain regions: periventricular 
hyperintensities (PVH), basal ganglia hyperintensities (BGH), deep white matter, which 
in this article is called lobar (lobar-WMHs, with its frontal, temporal, parietal, and 
occipital subscores), and infratentorial. The total score was obtained by the sum of the 
Scheltens subscores. Rating of WMHs was performed by evaluating the number, size, 
and localization of the lesions (Data S1). 
 
 
Statistical analysis 
 
Clinical characteristics and scale scores in the cross-sectional study were analyzed using 
Fisher's exact test for categorical variables, ANOVA for continuous normally 
distributed variables, and the Kruskal–Wallis test and a percentile bootstrap method for 
non-normal distribution. The normal distribution of the residuals and the 
homoscedasticity were tested. For the WMHs subscales, we applied a multivariate 
normative comparison [25] followed by a chi-square analysis to test whether the 
percentage of cases with higher WMHs scores in cognitively impaired groups differed 
from an expected percentage of 5% (type I error). 
 
To evaluate how the distribution of WMHs might affect specific cognitive domains, a 
nonparametric Spearman correlation analysis was performed and adjusted for multiple 
comparisons with Bonferroni's correction. The significant P-values corrected for 
multiple comparisons were selected and assessed in a multiple linear regression model 
which was adjusted for confounding variables, taking each of the cognitive test scores 
as the dependent variable. 
 
For the prospective study, an association between the change in the cognitive category 
(cognitively normal, MCI, or dementia) and the increase in the different WMHs 
Scheltens scores was tested by a Fisher's exact test. A mixed two-factor general linear 
model was employed to assess the changes in the cognitive results as a function of the 
baseline WMHs lesion burden or of the increase in the radiological score. A normal 
distribution of the residuals was determined and Mauchly's test of sphericity was 
performed. To normalize the data, a power transformation was estimated with the 
Applied Linear Regression statistics package using the “R” programming language and 
for the robust methods R.R. The P-values obtained for the different Scheltens subscales 
were corrected with Bonferroni's correction. Wilcox's robust statistics functions package 
was used. The statistical analysis was performed using SPSS 15.0 (SPSS15, Inc., 
Chicago IL, USA) and R 2.11.1. (Development Core Team. R: A language and 
environment for statistical computing R Foundation for Statistical Computing, Vienna, 
Austria). 
 
 
 
RESULTS 
 
One hundred and eleven patients with PD classified as PDCN (n = 39), PD-MCI (n = 
46), or PDD (n = 26) were studied. The general demographic and clinical features are 
summarized in Table 1. Patients with dementia were older, had higher depression 
scores, and more severe parkinsonism than the PDCN and PD-MCI groups. In addition, 
the PDCN group was more educated and showed lower depression scores than the PD-
MCI patients. The prevalence of vascular risk factors was evenly distributed among the 
three groups of patients. 
 
The Scheltens scale scores for the three groups of patients are summarized in Table 2. 
Owing to shortage of lesions in the parietal and occipital lobes, WMHs in both lobes 
were merged. The inter-rater and intra-rater agreements were measured using the intra-
class correlation coefficient. The resulting values for the different scores ranged from 
0.73 to 0.93 for the former and from 0.89 to 0.97 for the later, indicating a high degree 
of agreement. No difference in the total score or in the subcores was found amongst the 
three groups of patients (Table 2). The multivariate normative comparison for the 
subscores found that three patients with dementia and five patients with MCI had higher 
scores than PDCN patients. However, this number of cases was not significantly 
different from the expected (P = 0.12 for PD-MCI and P = 0.13 for PDD patients). 
 
The infratentorial score was not considered for correlation studies and for follow-up 
because of the scarce number of patients presenting WMHs in this region (Table 2). In 
an ordinal logistic regression controlling for the education level attained, age, UPDRS-
III, and GDS scores, the total WMHs score had no effect on cognitive status (P = 0.58, 
Nagelkerke R-square of the complete model R = 0.58). None of the WMHs subscores 
(lobar, PVH, and BGH) were either significant. Furthermore, the relationship between 
the total score and MMSE was tested in a linear multiple regression model adjusted for 
age, attained educational level, and GDS score, and no predictive value was found (P = 
0.70; R2 = 0.36). 
 
The relationship between the subscores for the distinct lobar regions (frontal, temporal, 
and parieto-occipital) and the neuropsychological scores for the tests evaluating each 
cognitive domain was assessed by nonparametric correlations (Table 3). There was a 
negative correlation between semantic fluency and the frontal score after Bonferroni–
Holmes correction was applied (P = 0.01; r = -0.29). To further study this association, 
the frontal individual scores were grouped into four clinical categories according to the 
lesion burden (absent = 0, mild = 1–2, moderate = 3–4, and severe = 5–6) and entered in 
a linear regression model as an independent variable adjusting for confounding factors 
(educational level, age, and GDS score). In this analysis, semantic fluency was also 
associated with the frontal score (P = 0.048). Although no linear trend could be found 
between the four categories and semantic fluency scores (P = 0.057), the category with 
severe lesion burden had a significantly lower semantic fluency score than the other 
categories grouped (absent, mild, and moderate) indicating a threshold effect of frontal 
WMHs burden on semantic fluency (P = 0.008; difference, -2.83 words; 95%CI, -0.75 
to -4.85). 
  
 
  
LONGITUDINAL STUDY 
 
From the initial cohort of 86 patients with PD, 36 were re-evaluated 12–48 months after 
the initial assessment (12–24 months, nine patients, 24–36 months, 18 patients; 36–48 
months, nine patients; mean = 30.1  months) (Fig. 1). The clinical features of this cohort 
were not different from those of the non-demented patients excluded from this analysis 
(n = 49). 
 
Three PDCN patients progressed to MCI and 1 to dementia. Four patients with PD-MCI 
progressed to dementia. None of the PD-MCI patients normalized to PDCN. In the 
group followed between 12 and 24 months, no patient showed a change in cognitive 
diagnosis. In patients followed between 24 and 36 months, one subject progresses from 
MCI to dementia, and another one from cognitively normal to MCI. After 36–48 
months, three patients progressed from MCI to dementia, two from cognitively normal 
to MCI, and one patient from cognitively normal to dementia. The three groups of 
patients did not show differences at baseline in MMSE score (P = 0.14) or age (P = 
0.67). 
 
A number of patients showed progression of WMHs scores (Table 4). Increasing total, 
lobar, and BGH subscores of the Scheltens scale were not associated with progression 
to a more cognitively impaired diagnostic category (MCI or dementia). However, an 
increase in the PVH subscore was associated with an increased conversion to dementia 
after adjusting for multiple comparisons (P-value corrected, 0.02). There was no 
association between an increase in the total WMHs and the change in MMSE 
performance adjusted for age (P-value for interaction = 0.054). This result was also 
observed for the lobar-WMHs score, but the effect disappeared after correction for 
multiple comparisons (corrected P-value for interaction = 0.13). Changes in semantic 
verbal fluency with respect to baseline were not significantly affected by an increase in 
the frontal Scheltens subscore (P = 0.21). 
 
 
 
DISCUSSION 
 
The primary finding of this study is that WMHs are not different in the distinct 
cognitive states of PD patients with no prior relevant vascular disease. However, there is 
a mild impact of the increment of WMHs (periventricular and total burden) in the 
progression of cognitive decline. Owing to the small sample size and the excessive 
attrition of the sample at follow-up, this finding needs to be interpreted with caution and 
needs further confirmation in larger longitudinal studies. In addition, vascular burden 
may have a mild effect on certain tasks of executive performance, as witnessed by the 
negative correlation between semantic fluency and the frontal subscore on the Scheltens 
scale. 
 
Although cognitive decline in PD is associated with cholinergic degeneration [26], 
limbic and neocortical LB, AD, and vascular pathology [27], the link between these 
factors, neuronal loss, and clinical symptoms is ill defined [28]. CV pathology 
constitutes a risk factor for dementia and cognitive decline in the general population 
[29], and it also appears to be relevant in AD [13]. However, whilst CV lesions have 
been proposed to play an important role in PD dementia, this relationship remains to be 
fully demonstrated [5–8]. Indeed, large neuropathological studies have failed to confirm 
a significant influence of ischaemic CV alterations on cognitive impairment in patients 
with PD [5], and cognitive deficiencies appear to be independent of coexisting CV 
pathology, except when it is severe [6]. 
 
Silent vascular lesions, identified as WMHs in MRI images, probably correspond to 
areas of demyelization and astrocytic gliosis. In addition to the neuronal dysfunction 
caused by the neurodegenerative process, these white matter pathologies might 
aggravate the already-defective neuronal connectivity and therefore increase the 
cognitive dysfunction. Thus, WMHs have been associated with dementia in the general 
population [10–12, 30–33] and also represents an aggravating factor in cognitive 
impairment in AD [13] and LB dementia [14]. Moreover, WMHs have been related to a 
high risk of MCI and a greater decline in global cognitive performance, executive 
function, and processing speed [15]. In PD, the relationship between WMHs, MCI, and 
dementia remains unclear [16–19,23,34]. 
 
Cross-sectional studies have reported that WMHs burden and cognitive impairment are 
not associated in PD [16,19,23,34]. Actually, WMHs was not found to contribute to 
either MCI or attention-executive dysfunction in a cohort of newly diagnosed and 
untreated patients with PD [19], and WMHs severity was similar in advanced PD 
patients with dementia, MCI or with no cognitive disability [16]. 
 
By contrast, other studies reported more periven-tricular and deep WMHs in demented 
than in non-demented patients with PD [17,18], and an association between WMHs and 
lower MMSE scores [18]. These findings should be interpreted with caution, as in 
addition to the small sample size analyzed, there was no difference in the WMHs 
burden in PD patients with dementia when compared to control subjects, whilst non-
demented patients with PD exhibited fewer WMHs than controls [18]. 
 
We performed a cross-sectional and longitudinal study in a larger cohort of PD patients 
with more than 10 years of disease evolution, as this profile best represents the PD 
population at the highest risk of cognitive decline [35]. Although no differences in the 
WMHs scores in any of the Scheltens subscales were evident between different 
cognitive states in the cross-sectional study, in what we believe to be the first 
longitudinal study of its kind, an increment in periventricular WMHs was associated 
with an increased conversion to dementia. Moreover, a worsening in the MMSE was 
marginally associated with an increment in the total WMHs burden. Even though the 
follow-up period is long, our results are limited by the small number of patients, and 
therefore, larger prospective studies should be carried out. 
 
It has to be admitted that the image acquisition was performed in slice sections 5 mm 
apart, and very small lesions might have not been captured. However, this applies 
equally to every patient, and we do not believe it has a significant role in the outcome of 
this study. In addition, there was no change in the MRI scanner or in the methodology 
applied to obtain the images throughout the study, and the WMHs burden was evaluated 
blindly by two trained neurologists with a high inter- and intra-rater agreement. 
 
We also observed a negative correlation between semantic fluency and the frontal score, 
which persisted in a linear regression model analysis. In keeping with this finding, 
increased white matter abnormalities in frontal and cingulate regions are associated with 
executive dysfunction in MCI [36], and impairment in semantic fluency is more severe 
in non-demented PD patients with significant vascular lesions [37]. Our finding may 
reflect the dysfunction of the frontostriatal circuit in PD because of degeneration of the 
dopaminergic system that confers a selective vulnerability for specific executive 
functions whenever addtional lesions, as silent vascular insults, take place in the frontal 
lobe. 
 
In conclusion, the first longitudinal study evaluating the role of silent vascular lesions in 
the cognitive state of patients with PD indicates that although WMHs are not different 
in the distinct cognitive states, there is a mild impact of the increment of WMHs in the 
progression of cognitive decline. In addition, frontal WMHs in patients with PD have a 
negative impact on executive function. Prospective studies with larger cohorts and 
longer follow-up periods are guaranteed. 
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Table 1. General characteristics of the patients 
 
PDCN 
(n = 39) 
PD-MCI 
(n = 46) 
PDD 
(n = 26) 
p-values 
PD-groups 
Age
a
 68.0 (8) 72 (6) 74.0 (6) 0.001
b,c
 
PD evolution (years)
d
 13.3 (3.6) 13.4 (4.9) 14 (4.9) 0.959 
Gender (%men) 28 (71.8%) 28 (60.9%) 14 (53.8%) 0.314 
Levodopa equivalent 
dose
e
 (mg/day)
a
 
1000.0 (549) 1105.0 (604) 1000.0 (478) 0.627 
UPDRS-III “ON”a 12.0 (10.0) 17.0 (12.0) 20.0 (18.0) 0.032b 
UPDRS-III “OFF”d 32.28 (9.35) 34.16 (11.07) 44.61 (11.14) <0.001b,c 
Hoehn and Yahr
d
 2.83 (0.81) 2.84 (0.68) 3.6 (0.76) <0.001
b,c
 
GDS
a
 6.0 (6.0) 10.0 (7.0) 14.0 (5.0) <0.001
b,c,f
 
Education (years)
a
 10.0 (10.0) 5 (5.0) 5.0 (0.0) <0.001
b,c,f
 
DM 16.7% 10.3% 15.0% 0.761 
Hypertension 60.7% 52.9% 33.3% 0.150 
Hypercholesterolemia 16.7% 26.7% 10.5% 0.419 
Smoking 10.5% 21.1% 25.5% 0.564 
GDS, Yesavage Geriatric Depression Rating Scale; UPDRS-III, Unified Parkinson's 
Disease Rating Scale-motor section; DM, diabetes mellitus; 
a
Median (interquartile 
range); 
b
Significant differences between the PDD and the PDCN groups; 
c
Significant 
differences between the PDD and the PD-MCI groups; 
d
Mean (standard deviation); 
e
The levodopa equivalent daily dose was calculated for each patient as follows: L-dopa 
daily dose (mg) = L-dopa (mg) + L-dopa retard (mg)*0.77. In the case of 
entacapone/tolcapone co-administration, the L-dopa dose was multiplied by 1.33. For 
dopaminergic agonists, the formula used was Rotigotine (mg)*5 + Ropirinole (mg)* 20 
+ Pramiprexole (mg)*67 + Cabergoline (mg)*67 + Pergolide (mg)*100 [20]; 
f
Significant differences between the PDCN and the PD-MCI groups. 
 
 
 
 
 
 
 
Table 2. Summary of the Scheltens scale scores in the three groups of patients with PD 
 Total* PVH BGH 
Lobar-
WMHs 
Frontal Temporal 
Parieto-
occipital 
Infratentorial 
PDCN 
5           
(1–11) 
0  
(0–1) 
0  
(0–2) 
3  
(1–8) 
2 
(1–4) 
0 
(0–1) 
0  
(0–2) 
0  
(0–0) 
85.71% 28.6% 40.5% 84.2% 83.3% 45.23% 47.6% 17.07% 
PD-
MCI 
4.5       
(1–17) 
0         
(0–1.25) 
0  
(0–3) 
4  
(1–11.25) 
2  
(1–6) 
0  
(0–1) 
1  
(0–4) 
0  
(0–0) 
89.13% 41.3% 41.3% 87.3% 86.9% 45.65% 56.5% 17.77% 
PDD 
6  
(3–11) 
0  
(0–2) 
0            
(0–1.25) 
5  
(3–10.25) 
4            
(1.75–5) 
0.5  
(0–1) 
1  
(0–4) 
0  
(0–0.25) 
88.46% 46.2% 34.6% 89.5% 88.5% 50.00% 57.7% 20.22% 
PVH, periventricular hyperintensities; WMHs, white matter hyperintensities; BGH, basal 
ganglia hyperintensities; *P = 0.62, Uncorrected P-values obtained using a Kruskal–Wallis test; 
Median (1st and 3rd quartile); % of patients showing WMHs in each cerebral region; Lobar-
WMHs: it is the sum of the frontal, temporal, and parieto-occipital white matter lesions; Total: 
it is the sum of the subscores. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Summary of the correlation coefficients obtained between the Scheltens subscores 
assessing the white matter hyperintensities in the different brain areas and the 
neuropsychological tests scores evaluating their corresponding cognitive function. 
Scheltens 
subscale 
Cognitive domain Neuropsychological test 
Nonparametric 
correlation 
(corrected P-value) 
Frontal 
Attention and executive 
functions 
Raven progressive matrices 0.272 
  Semantic verbal fluency
a
 0.01 (r = -0.292) 
  Phonetic verbal fluency 1.0 
  Trail making A 1.0 
  
Stroop test color-word direct 
score 
1.0 
Temporal Verbal episodic memory Free recalls of Buschke 1.0 
  CERAD word list 1.0 
 Visual episodic memory 
Delayed recall of a geometric 
figure 
1.0 
 Language Boston naming test 0.284 
Parieto-
occipital 
Visual episodic memory Copy of a geometric figure 1.0 
  
Delayed recall of a geometric 
figure 
1.0 
 
Attention and executive 
functions 
Raven progressive matrices 1.0 
  Semantic verbal fluency
a
 0.185 
  Phonetic verbal fluency 1.0 
  Trail making A 1.0 
  
Stroop test color-word direct 
score 
1.0 
a
Verbal fluency in 1 min; Significant results were also encountered for fluency in 30 s; 
All the P-values are corrected using Bonferroni's correction. 
 
 
 
 
 
 
 
Table 4. Summary of the evolution of the Scheltens scale’s scores 
(unchanged/increased) and of the cognitive state (CN/MCI/D) over the follow-up              
(12–48 months) 
 Scale score follow-up Cognitive state follow-up 
Global WMHs Scheltens Unchanged 7 CN at baseline, 0 converted 
n = 36 n = 14 
7 MCI at baseline, 2 converted 
into D 
P = 0.68 
Increased  
n = 22 
11 CN at baseline, 3 converted 
into MCI and 1 into D 
 3 (2–5)a 
11 MCI at baseline, 2 converted 
into D 
Lobar-WMHs Scheltens Unchanged 8 CN at baseline, 0 converted 
n = 36 n = 16 
8 MCI at baseline, 2 converted 
into D 
P = 1.0 
Increased  
n = 20 
10 CN at baseline, 3 converted 
into MCI and 1 into D 
 3 (1–3.5)a 
10 MCI at baseline, 2 converted 
into D 
PV subscale Unchanged 
12 CN at baseline, 1 converted 
into D 
n = 36 n = 23 
11 MCI at baseline, 1 converted 
into D 
P = 0.020 Increased 
6 CN at baseline, 3 converted 
into MCI 
 n = 13 
7 MCI at baseline, 3 converted 
into D 
 1 (1–2)a  
BGH subscale Unchanged 
16 CN at baseline, 3 converted 
into MCI 
n = 36 n = 27 
11 MCI at baseline, 2 converted 
into D 
P = 1.0 
Increased  
n = 9 
2 CN at baseline, 1 converted 
into D 
 2 (1.5–3)a 
7 MCI at baseline, 2 converted 
into D 
CN, cognitively normal; MCI, mild cognitive impairment; D, dementia; WMHs, White 
matter hyperintensities; BG, basal ganglia; 
a
Median (interquartilic range) of the increase 
in the scores; P is the value obtained in the analysis to study whether the increments in 
the radiological scales predict a change in the cognitive diagnostic category. P-values 
are corrected for multiple comparisons. 
 
 
 
 
 
Figure 1. Flowchart of the follow-up of patients with Parkinson’s disease from 
baseline. DBS, deep brain stimulation; PD-D, Parkinson’s disease with dementia. 
 
 
 
 
 
 
